|
||
Articles |
,



Department of Molecular and Cellular Biology and the
Laboratory of Embryonic and Genetic Engineering, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan; and the || Department of Dermatology, Gunma University School of Medicine, Maebashi 371-8511, Japan
| Abstract |
|---|
|
|
|---|
–induced acceleration of neutrophil apoptosis did not differ among A1-a–/–, A1-a+/–, and wild-type mice. The descending order of A1 mRNA expression was wild-type, A1-a+/–, and A1-a–/–. Taken together, these results suggest that A1 is involved in inhibition of certain types of neutrophil apoptosis.
Key Words: neutrophil apoptosis A1 bcl-2–related gene gene disruption
Control of neutrophil function seems important for retaining an effective level of bacterial killing and other physiological properties while avoiding damage to normal tissues. The short life of neutrophils may ensure fulfillment of the latter requirement, since an early death after accomplishing their physiological task may prevent possible damage to normal tissues, which might occur with a prolonged survival of these cells. However, there are situations that require neutrophils to function actively for an extended period, such as during bacterial infection. In fact, these cells have been found to survive for longer periods in various situations. We have demonstrated previously that apoptosis of peritoneal exudate neutrophils (PEN)1 and peripheral blood neutrophils (PBN) obtained from rats intraperitoneally injected with inflammatory agents is severely inhibited (1). On the other hand, certain agents accelerate apoptosis of these cells. TNF-
Several genes have been implicated in the regulation of cell death, including those of the bcl-2 family (4–9), Fas/ Apo1 (10, 11), c-myc (12), p53 (13), and nur77 (14). Bcl-2, the bcl-2 product, blocks or delays cell death after administration of death-inducing agents or growth factor withdrawal (4). Analysis of bcl-2–deficient mice provided evidence that bcl-2 is required for ensuring the full life span of mature lymphocytes in vivo (15–17). A newly recognized member of the bcl-2 family, A1, was originally isolated from a cDNA library prepared from GM-CSF–treated mouse bone marrow cultures. Murine A1 is expressed in the thymus, spleen, and bone marrow, and specifically in the hematopoietic cell lineages including Th cells, macrophages, and neutrophils (9). Recently, a role for A1 in protection against apoptosis was reported (18–20). It has also been demonstrated that A1 is the only known Bcl-2 family member to be induced by the inflammatory cytokines TNF-
It has been shown that Bcl-2 and Bcl-xL can inhibit most apoptosis. Both of these proteins are absent in mature neutrophils although Bcl-2 is expressed in early myeloid cells of the bone marrow (22). Expression of a newly recognized member of the Bcl-2 family, A1, alone of all the known proteins that inhibit neutrophil apoptosis, suggests that A1 plays a major role in the prevention of this apoptosis. We have reported previously that in the murine genome A1 consists of at least four genes, A1-a, -b, -c, and -d (23), all of which have a high degree of homology with each other at the nucleotide and amino acid sequence levels. In this study, we used gene targeting to establish mice lacking A1-a, one of the A1 subtypes (A1-a–/– mice), in order to investigate the possible role of A1-a in the regulation of neutrophil apoptosis. We describe here acceleration of neutrophil apoptosis in A1-a–/– mice and discuss its possible mechanisms.
Animals.
Preparation of PBN.
Preparation of PEN.
Neutrophil Culture.
Examination of Neutrophil Apoptosis.
enhances apoptosis of human (2) and rat (1) neutrophils, and PMA induces prompt neutrophil death, although in a different manner from that of typical apoptosis or necrosis (3). However, the mechanisms responsible for the regulation of neutrophil apoptosis remain largely unknown.
and IL-1β (21).
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Establishment of the A1-a–/– Mouse.
Genomic DNA corresponding to the A1-a locus was isolated from a library of 129Sv mouse DNA (Stratagene Inc., La Jolla, CA). The XbaI-HindIII fragment (4 kb), containing exon 1 of the A1-a coding region (1– 140 amino acids), was deleted and replaced with a PGK-neo-polyadenylate [poly(A)] cassette. The targeting vector, pA1-a-KO-neo, contains a 1.1 kb of homology 5', 6.0 kb 3' of the drug-resistant gene, and a PGK-tk-poly(A) cassette. The linearized pA1-a-KO-neo was transfected into E14 embryonic stem (ES) cells. For screening of A1-a-KO targeted clones by PCR, an A1-a flanking primer (5'-CATCATAGTTTGTCATTCAGGAAG-3') and a PGK-poly(A)-specific primer (5'-GGGTGGGGTGGGATTAGATAAATG-3') were used. PCR-positive clones were analyzed by Southern blot hybridization to confirm that there had been homologous recombination. Mutated ES cells were microinjected into C57BL/6 blastocysts that were then implanted into uteri of pseudopregnant ICR mice to generate chimeric offspring. Male chimeric mice were mated with C57BL/6 females, and A1-a+/– mice were intercrossed to obtain A1-a–/– mice. Maintenance, transfection, and selection were carried out as described previously (24).
A1-a–/– mice and A1-a+/– mice were maintained in the animal center of our medical school in an environment kept free of pathogenic bacteria. The genotypes of newborn mice were examined by PCR at 4–8 wk of age. PCR was performed using genomic DNA obtained from a tail biopsy specimen. Two oligonucleotide primers, 5'-ATGGCTGAGTCTGAGCTCATG-3' and 5'-CCAACCTCCATTCCGCCGTATC-3', were used for endogenous detection, and two other primers, 5'-CATCATAGTTTGTCATTCAGGAAG-3' and 5'-GGGTGGGGTGGGATTAGATAAATG-3', were used for detecting knockouts. C57BL/6 and 129Sv mice were used as controls. The mice used for experiments had body weights of 25–35 g.
We separated PBN from blood using a partially modified method of Tsuchida et al. (1). Heparinized peripheral blood was obtained by cardiac puncture. Blood from three to seven mice of the same group was usually pooled together to obtain a sufficient number of PBN for the apoptosis assay. RBCs were sedimented by the addition of an equal volume of 3% (wt/vol) dextran T-500 (25) (Pharmacia Biotech AB, Uppsala, Sweden) in PBS. The mixture of blood and dextran was allowed to stand in a 15-ml conical tube (Falcon FAL2096; Becton Dickinson Labware, Lincoln Park, NJ) at room temperature for 12–15 min to permit the erythrocytes to sediment. The leukocyte-rich supernatant (buffy coat) was transferred to another conical tube which was then filled with Eagle's MEM (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) and centrifuged at 650 g for 5 min at 4°C. The leukocyte-rich erythrocyte layer at the bottom was suspended in 5 ml of MEM and centrifuged on 5 ml of Ficoll-Paque (specific gravity, 1.077; Pharmacia Biotech AB) at 800 g for 10 min at 4°C. The erythrocytes in the pellet were lysed by hypotonic shock. Neutrophils were washed with MEM, resuspended in RPMI 1640 medium (GIBCO BRL, Gaithersburg, MD) supplemented with 10% FCS (Whittaker M.A. Bioproducts, Inc., Walkersville, MD), and used for experiments. The purity obtained was
85–95%.
Mice were injected intraperitoneally with 4–5 ml of 3% proteose peptone (Difco Laboratories Inc., Detroit, MI). 12 h later each mouse received the same injection again. 3 h after the second injection mice were killed and PEN were harvested twice by peritoneal lavage with 4 ml of cold heparinized MEM. The cell suspension was washed by centrifugation at 650 g for 5 min at 4°C and the pellet was resuspended in 5 ml MEM and centrifuged on 5 ml of Ficoll-Paque at 800 g for 10 min at 4°C. The neutrophils were washed with MEM and resuspended in RPMI 1640 supplemented with 10% FCS and then used for experiments. The approximate purity obtained was >95%.
Aliquots (0.4 ml) of neutrophil suspensions (0.5 x 106/ml) were seeded into 8-well culture slides (Falcon FAL4118; Becton Dickinson Labware) and incubated at 37°C for varying periods of time in a 5% CO2 atmosphere. Neutrophils were cultured in the presence or absence of recombinant human TNF-
(gift from Dainippon Pharmaceutical Co., Ltd., Tokyo, Japan) or LPS (Difco Laboratories Inc.). The concentration of endotoxin in the FCS used was <100 pg/ml.
Neutrophils incubated under specific conditions were stained with May-Giemsa and apoptotic cells were counted under light microscopy (x1,000). Representative microscopic images of normal and apoptotic neutrophils are shown in Fig. 1. Approximately 300–1200 cells were scanned per specimen.
|
DNA with primers 5'-ATTTAGGTGACACT AT AGA A TACA A T TCCA A CAG C C TCCAGATATG - 3 ' and 5'-GAAACAAAATATCTGCAACTCTGGAGAGTTTCTGCGGCAGTTAA-3' using a competitive DNA construction kit (TaKaRa). 1–109 copies of the DNA competitors were prepared by a 10-fold dilution and amplified in a DNA Thermal Cycler with 1 µl of first-strand cDNA in reaction volumes of 50 µl using primers 5'-AATTCCAACAGCCTCCAGATATG-3' and 5'-GAAACAAAATATCTGCAACTCTGG-3' together with 0.625 U Ex-Taq polymerase. PCR products were electrophoresed on 2% agarose gels, and the strengths of target bands were compared visually with the competitor bands for each lane.
Data Analysis.
Results were expressed as means of at least five independent experiments. Statistical significance was determined by the unpaired t test.
| Results |
|---|
|
|
|---|
4.5 kb. The targeting construct was designed to delete the protein coding region of exon 1 (Fig. 2 A). Electroporation of the linearized targeting vector and G418/gancyclovir selection for homologous recombinants were carried out as described in Materials and Methods. G418/gancyclovir double-resistant ES cell clones (67 clones) were screened for homologous recombination events by PCR, and two clones (3.0%) were found to have recombined homologously. All of these clones were confirmed by Southern blot analysis to contain the desired targeted allele (Fig. 2 B). The two clones were injected into C57BL/6 blastocysts, and high coat-color chimeric males that transmitted the mutant allele to the germline were obtained. Heterozygous offspring of chimeras appeared entirely normal and were fertile. To determine the relative expression level of mRNA of each A1 subtype, RNA obtained from neutrophils was amplified. The RT-PCR products were then digested with the restriction enzymes BglII and NsiI to distinguish each subtype. Expression ratios of each subtype were as follows: among the A1-a–/– mice, the A1-b/A1-d ratio was 3:2; and in A1-a+/– mice, the A1-a/A1-b/A1-d ratio was 4:7:6 (data not shown). Ratios for wild-type mice were as follows: among C57BL/6 mice, the A1-a/A1-b/A1-d ratio was 3:4:3; and in 129Sv mice, this ratio was 7:8:5 (23).
|
|
Accelerated Spontaneous Apoptosis of PBN in A1-a–/– Mice.
Several groups have reported that transfection of A1 into cell lines prolongs cell survival (18–20). However, there has been no report evaluating the relationship between endogenous A1 and apoptosis. To determine whether A1-a plays a role in neutrophil apoptosis, we studied the spontaneous apoptosis of PBN obtained from A1-a–/– mice. We first examined spontaneous apoptosis of PBN from control C57BL/6 and 129Sv mice. Since there was no difference in PBN apoptosis within these two strains (data not shown), we used mice of these groups as wild-type controls. Spontaneous apoptosis of PBN obtained from wild-type and A1-a+/– mice gradually increased during incubation in vitro, and there was no significant difference between these two groups. On the other hand, spontaneous apoptosis of PBN from A1-a–/– mice was significantly greater than that of wild-type or A1-a+/– mice at 12 and 24 h of incubation (Fig. 4).
|
|
|
Lack of Change in Sensitivity to TNF-
–enhanced Neutrophil Apoptosis in A1-a–/– Mice.
We demonstrated previously that TNF-
enhances apoptosis of human (2) and rat (1) neutrophils. To further explore possible mechanisms for the enhancement of spontaneous apoptosis of PBN in A1-a–/– mice, we examined the sensitivity of these PBN in terms of TNF-
enhancement of apoptosis. Treatment with this cytokine enhanced PBN apoptosis in all wild-type, A1-a+/–, and A1-a–/– mice at a 12 h incubation (Fig. 5). The extent of apoptosis enhancement by TNF-
was not significantly different among these three groups of mice (data not shown). On the other hand, apoptosis of PEN was not enhanced in any of the A1-a–/–, A1-a+/–, or wild-type mice by TNF-
(Fig. 5), similar to our results obtained previously with normal rats (1).
|
| Discussion |
|---|
|
|
|---|
Our present finding that A1-a–/– mice exhibit enhanced neutrophil apoptosis further strengthens the assumption that A1 is a major suppressor of this process. Furthermore, the finding that knockout of the A1-a subtype results in enhancement of neutrophil apoptosis suggests that this subtype functions as an important suppressor of apoptosis of these cells. However, inasmuch as cycloheximide treatment of neutrophils of wild-type mice induces greater apoptosis than that of A1-a–/– (Hamasaki, A., unpublished results), the other subtypes, A1-b and A1-d, may also be involved in neutrophil apoptosis inhibition.
It has been shown previously that treatment of neutrophils in vitro with cytokines such as IL-1 (26), G-CSF (26), GM-CSF (26, 28, 29), and IFN-
(26), which are detectable in inflammatory foci, inhibits apoptosis of these cells. Furthermore, endothelial transmigration in vitro (30) and in vivo (1) both delay neutrophil apoptosis. The present finding that neutrophil apoptosis inhibition by LPS in vitro and transendothelial migration in vivo were completely abrogated in A1-a–/– mice strongly suggests that A1-a is involved in this inflammation-mediated suppression of apoptosis.
The present finding that spontaneous neutrophil apoptosis is accelerated in A1-a–/– mice (Fig. 4) suggests that A1-a is also involved in this suppression of apoptosis. The constitutive expression of A1 mRNA in neutrophils of untreated wild-type mice supports this assumption. As the mechanisms involved in spontaneous neutrophil apoptosis, autocrine death induced by Fas/FasL interaction on the neutrophil surface (37), reactive oxygen intermediates (38, 39), and caspase (40), have been suggested as playing an active role in effector mechanisms, which may not necessarily be mutually exclusive, and which may actually be interactive to some degree. An examination of candidate mechanisms and the manner in which A1 modulates apoptosis will be the focus of future studies on A1 involvement in spontaneous neutrophil apoptosis inhibition.
The finding in this study that inhibition of PEN and LPS-treated PBN apoptosis was abrogated in both A1-a–/– and A1-a+/– mice, whereas acceleration of spontaneous PBN apoptosis was observed in A1-a–/– alone (Table 1), may be explained as follows: in untreated PBN, the concentration of A1 protein in A1+/– may be sufficient to inhibit apoptosis, since mRNA expression of A1 in these mice is 10-fold higher than in A1-a–/–, but only one tenth that of wild-type 129Sv mice (Table 2). However, a greater concentration of A1 protein may be required to inhibit apoptosis of LPS-treated PBN or extravasated PEN, which may explain the lack of inhibition in A1-a–/– and A1-a+/– mice.
Our finding that TNF-
–induced acceleration of neutrophil apoptosis was not augmented in A1-a–/– is apparently inconsistent with the previous finding that transfection of the A1 gene into an endothelial cell line resulted in inhibition of TNF-
–induced apoptosis of these cells (19). This apparent discrepancy may be reconciled as follows: first, although the discoveries of TNF receptor-binding cytoplasmic proteins such as TNF receptor 1-associated death domain protein (41) and TNF receptor–associated factor (42, 43) have expanded our understanding of the mechanisms of TNF-
–induced apoptosis, the picture is far from clear. Various molecules such as IL-1β–converting enzyme–like protease (44), ceramide (45, 46), reactive oxygen intermediates (47), and nicotinamide dinucleotide (48) have been proposed as candidates for mediators of TNF-
– induced apoptosis. On the other hand, nitric oxide (49) and A20 zinc finger protein (50) are both thought to be inhibitors of this form of apoptosis. Apoptosis induction and inhibition through mechanisms involving the above molecules are dependent on cell type (44–50). Therefore, signal transductions governing TNF-
–induced apoptosis may differ in neutrophils and endothelial cells. Secondly, a difference in the manner of TNF-
–induced apoptosis of the two cell types may explain the discrepancy in the results, i.e., why addition of actinomycin D is required for TNF-
– induced apoptosis of endothelial cells (19) while TNF-
alone is sufficient to induce neutrophil apoptosis (1, 2). In addition, our preliminary results suggesting that the GM-CSF–induced inhibition of neutrophil apoptosis was not abolished in A1-a–/– mice (Hamasaki, A., unpublished results) themselves suggest that there exist systems of neutrophil apoptosis regulation other than those shown in this manuscript.
The unexpected result that the number of PBN and PEN was not significantly different in A1-a–/–, A1-a+/–, and wild-type mice may be explained as follows: (a) various systems other than A1, involved in the regulation of neutrophil apoptosis may compensate for this apoptosis in vivo; (b) positive feedback regulation of PBN number may be induced in A1-a–/– mice through cytokines such as G-CSF; and (c) a less probable possibility is that preapoptotic change in cell surface carbohydrates which induce phagocytosis by macrophages (51) may not differ between A1-a–/–, A1-a+/–, and wild-type mice and this may result in the same grade of phagocytosis of preapoptotic neutrophils in these strains of mice.
Studies are now in progress to more precisely elucidate the mechanisms of A1 involvement in the inhibition of neutrophil apoptosis and to examine whether A1 is also involved in the inhibition of apoptosis of myeloid cells other than neutrophils.
| Acknowledgments |
|---|
Submitted: 16 March 1998
Revised: 28 September 1998
1 Abbreviations used in this paper: ES, embryonic stem cells; PBN, peripheral blood neutrophils; PEN, peritoneal exudate neutrophils.
| References |
|---|
|
|
|---|
1 Tsuchida H, Takeda Y, Takei H, Shinzawa H, Takahashi T & Sendo F. In vivo regulation of rat neutrophil apoptosis occurring spontaneously or induced with TNF-
or cycloheximide, J Immunol, 1995, 154, 2403–2412.[Abstract]
2 Takeda Y, Watanabe H, Yonehara S, Yamashita T, Saito S & Sendo F. Rapid acceleration of neutrophil apoptosis by tumor necrosis factor-
, Int Immunol, 1993, 5, 691–694.
3 Takei H, Araki A, Watanabe H, Ichinose A & Sendo F. Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis, J Leukoc Biol, 1996, 59, 229–240.[Abstract]
4 Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP & Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor- deprived hemopoietic cell lines, J Immunol, 1990, 144, 3602–3610.[Abstract]
5 Boise LH, González-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G & Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death, Cell, 1993, 74, 597–608.[Medline]
6 Oltvai ZN, Milliman CL & Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death, Cell, 1993, 74, 609–619.[Medline]
7 Yang E, Zha J, Jockel J, Boise LH, Thompson CB & Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-xLand Bcl-2, displaces Bax and promotes cell death, Cell, 1995, 80, 285–291.[Medline]
8 Kozopas KM, Yang T, Buchan HL, Zhou P & Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2, Proc Natl Acad Sci USA, 1993, 90, 3516–3520.
9 Lin EY, Orlofsky A, Berger MS & Prystowsky MB. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. , J Immunol, 1993, 151, 1979–1988.[Abstract]
10 Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y & Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell, 1991, 66, 233–243.[Medline]
11 Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC et al.. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen, J Biol Chem, 1992, 267, 10709–10715.
12 Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP & Green DR. Role for c-mycin activation- induced apoptotic cell death in T cell hybridomas, Science, 1992, 257, 212–214.
13 Lowe SW, Schmitt EM, Smith SW, Osborne BA & Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature, 1993, 362, 847–849.[Medline]
14 Woronicz JD, Calnan B, Ngo V & Winoto A. Requirement for the orphan steroid receptor Nur77in apoptosis of T-cell hybridomas, Nature, 1994, 367, 277–281.[Medline]
15 Nakayama K-i, Nakayama K, Negishi I, Kuida K, Louie MC, Kanagawa O, Nakauchi H & Loh DY. Requirement for CD8 β chain in positive selection of CD8-lineage T cells, Science, 1994, 263, 1131–1133.
16 Nakayama K, Nakayama K-i, Negishi I, Kuida K, Sawa H & Loh DY. Targeted disruption of Bcl-2
β in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia, Proc Natl Acad Sci USA, 1994, 91, 3700–3704.
17 Veis DJ, Sorenson CM, Shutter JR & Korsmeyer SJ. Bcl-2–deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair, Cell, 1993, 75, 229–240.[Medline]
18 Lin EY, Orlofsky A, Wang HG, Reed JC & Prystowsky MB. A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation, Blood, 1996, 87, 983–992.
19 Karsan A, Yee E & Harlan JM. Endothelial cell death induced by tumor necrosis factor-
is inhibited by the Bcl-2 family member, A1, J Biol Chem, 1996, 271, 27201–27204.
20 Carrió R, López HM, Jimeno J, Benedict MA, Merino R, Benito A, Fernández LJ, Núñez G, García PJ & Merino J. A1demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death, Am J Pathol, 1996, 149, 2133–2142.[Abstract]
21 Karsan A, Yee E, Kaushansky K & Harlan JM. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells, Blood, 1996, 87, 3089–3096.
22 Ohta K, Iwai K, Kasahara Y, Taniguchi N, Krajewski S, Reed JC & Miyawaki T. Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X, and Mcl-1 in human peripheral blood and lymphoid tissues, Int Immunol, 1995, 7, 1817–1825.
23 Hatakeyama S, Hamasaki A, Negishi I, Loh DY, Sendo F, Nakayama K & Nakayama K-i. Multiple gene duplication and expression of mouse bcl-2related genes, A1, Int Immunol, 1998, 10, 631–637.
24 Nakayama K-i, Nakayama K, Negishi I, Kuida K, Shinkai Y, Louie MC, Fields LE, Lucas PJ, Stewart V, Alt FW & Loh DY. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice, Science, 1993, 261, 1584–1588.
25 Wahba AV, Barnes B & Lazarus GS. Labeling of peripheral blood polymorphonuclear leukocytes with indium-111: a new method for the quantitation of in-vivo accumulation of PMNLs in rabbit skin, J Invest Dermatol, 1984, 82, 126–131.[Medline]
26 Colotta F, Re F, Polentarutti N, Sozzani S & Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products, Blood, 1992, 80, 2012–2020.
27 Hachiya O, Takeda Y, Miyata H, Watanabe H, Yamashita T & Sendo F. Inhibition by bacterial lipopolysaccharide of spontaneous and TNF-
–induced human neutrophil apoptosis in vitro, Microbiol Immunol, 1995, 39, 715–723.[Medline]
28 Brach MA, deVos S, Gruss HJ & Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death, Blood, 1992, 80, 2920–2924.
29 Lee A, Whyte MK & Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators, J Leukoc Biol, 1993, 54, 283–288.[Abstract]
30 Watson RW, Rotstein OD, Nathens AB, Parodo J & Marshall JC. Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement, J Immunol, 1997, 158, 945–953.[Abstract]
31 Naumovski L & Cleary ML. Bcl2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells, Blood, 1994, 83, 2261–2267.
32 Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della G & Porta. bcl-2proto-oncogene expression in normal and neoplastic human myeloid cells, Blood, 1992, 79, 1291–1298.
33 Vaux DL, Cory S & Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-mycto immortalize pre-B cells, Nature, 1988, 335, 440–442.[Medline]
34 Lagasse E & Weissman IL. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages, J Exp Med, 1994, 179, 1047–1052.
35 Gottschalk AR, Boise LH, Thompson CB & Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2, Proc Natl Acad Sci USA, 1994, 91, 7350–7354.
36 Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A & Craig RW. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells, Cancer Res, 1994, 54, 6348–6352.
37 Liles WC, Kiener PA, Ledbetter JA, Aruffo A & Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils, J Exp Med, 1996, 184, 429–440.
38 Kasahara Y, Iwai K, Yachie A, Ohta K, Konno A, Seki H, Miyawaki T & Taniguchi N. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils, Blood, 1997, 89, 1748–1753.
39 Narayanan PK, Ragheb K, Lawler G & Robinson JP. Defects in intracellular oxidative metabolism of neutrophils undergoing apoptosis, J Leukoc Biol, 1997, 61, 481–488.[Abstract]
40 William R, Watson G, Rotstein OD, Parodo J, Bitar R, Hackam D & Marshall JC. Granulocytic differentiation of HL-60 cells results in spontaneous apoptosis mediated by increased caspase expression, FEBS (Fed Eur Biochem Soc) Lett, 1997, 412, 603–609.
41 Hsu H, Xiong J & Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-
B activation, Cell, 1995, 81, 495–504.[Medline]
42 Rothe M, Wong SC, Henzel WJ & Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor, Cell, 1994, 78, 681–692.[Medline]
43 Rothe M, Sarma V, Dixit VM & Goeddel DV. TRAF2-mediated activation of NF-
B by TNF receptor 2 and CD40, Science, 1995, 269, 1424–1427.
44 Enari M, Hug H & Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis, Nature, 1995, 375, 78–81.[Medline]
45 Obeid LM, Linardic CM, Karolak LA & Hannun YA. Programmed cell death induced by ceramide, Science, 1993, 259, 1769–1771.
46 Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA & Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway, Proc Natl Acad Sci USA, 1994, 91, 73–77.
47 Schulze-Osthoff K, Krammer PH & Droge W. Divergent signaling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death, EMBO (Eur Mol Biol Organ) J, 1994, 13, 4587–4596.[Medline]
48 Wright SC, Wei QS, Kinder DH & Larrick JW. Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide–deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation, J Exp Med, 1996, 183, 463–471.
49 Dimmeler S, Haendeler J, Nehls M & Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases, J Exp Med, 1997, 185, 601–607.
50 Jaattela M, Mouritzen H, Elling F & Bastholm L. A20 zinc finger protein inhibits TNF and IL-1 signaling, J Immunol, 1996, 156, 1166–1173.[Abstract]
51 Savill J, Dransfield I, Hogg N & Haslett C. Vitronectin receptor–mediated phagocytosis of cells undergoing apoptosis, Nature, 1990, 343, 170–173.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|